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Abstract: Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small
cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with
pembrolizumab. We present a case of acute kidney injury in a patient on pembrolizumab who was
noted to have acute tubulointerstitial nephritis on renal biopsy. Pembrolizumab was discontinued
and the patient was started on long-term corticosteroids with a taper. Her renal function improved
partially with treatment.
Keywords: pembrolizumab; acute kidney injury; programmed cell death 1 inhibitor; non-small cell
lung cancer

1. Introduction
Pembrolizumab is an immune checkpoint inhibitor (CPI) approved by the United States Food
and Drug Administration for use in non-small cell lung carcinoma (NSCLC) [1–3]. It prevents the
suppression of T-cell activation by inhibiting binding of programmed cell death ligand (PD-L1)
produced by tumor cells to the inhibitory programmed cell death (PD-1) receptor expressed on the
surface of T-cells [1,2,4]. By doing this, T-cells can mediate an antitumor response. Pembrolizumab
has been associated with side effects like fatigue, pruritus, and decreased appetite. Renal toxicity was
not seen in initial reports [5]. Since then, renal adverse effects in association with CPIs have been
described [2,4]. We present a case of NSCLC on pembrolizumab found to have acute kidney injury
during hospitalization for chest and abdominal pain. Informed consent was obtained from the patient
for submission of the case.
2. Case Description
The patient is a 62-year-old woman who was brought to the emergency department (ED) with 2
episodes of sudden onset substernal chest pain, each episode lasting for 30 min. Her chest pain had
resolved at the time of arrival. Prior to that, she had felt nauseous which was usual for her after her
chemotherapy. Chest pain was followed by right-sided, sharp diffuse abdominal pain which lasted
for 10 min and resolved spontaneously. She had received her last chemotherapy infusion 2 days
prior to the episode. She denied any fever, chills, cough or shortness of breath. She was diagnosed
of NSCLC with bone metastases (epidermal growth factor receptor negative and PD-L1-80%) a year
ago for which she underwent radiation therapy of left hip and right upper ribs, completed palliative
chemotherapy with 6 cycles of pemetrexed 500 mg/m2 /dose, carboplatin 550 mg, and pembrolizumab
200 mg followed by same doses of pemetrexed and pembrolizumab maintenance every 3 weeks
with last dose 2 days prior to presentation. The patient had been on pembrolizumab for 6 months
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prior to the decline in renal function. Other past medical history included stage IA right breast
cancer (estrogen receptor+ (90%), progesterone receptor+ (3–5%), and human epidermal growth
factor receptor 2-negative invasive ductal carcinoma) for which she underwent a bilateral mastectomy,
6 cycles of cyclophosphamide, methotrexate, and fluorouracil, and tamoxifen for 5 years 20 years ago,
hypothyroidism, and hyperlipidemia. Her home medications included levothyroxine 75 µg daily, folic
acid 1 mg daily, pantoprazole 40 mg daily, rosuvastatin 5 mg nightly, dexamethasone 8 mg two doses
before and after chemotherapy, olanzapine 10 mg nightly, lorazepam 0.5 mg as needed, ondansetron
8 mg as needed, prochlorperazine 10 mg as needed, and promethazine 25 mg as needed. She had
smoked a pack a day for 15 years before quitting 27 years ago.
On examination, vitals were stable with a temperature of 36.7 ◦ C (98.1 ◦ F), blood pressure
139/82 mm Hg, pulse 79 beats per minute, respiratory rate 18 breaths per minute, and she was
maintaining saturation on room air. Chest, cardiac, and abdominal examinations were unremarkable.
Her hemoglobin was 9.1 g/dL (reference range: 12.0–16.0 g/dL), platelet count was 556,000/µL (reference
range: 13,000–400,000/µL), and white count was 10,700/µL (reference range: 4800–10,800/µL) with
neutrophil count of 9800/µL (reference range: 2000–8000/µL), monocyte count of 400 (reference range:
100–1300/µL), and immature granulocyte count of 260/µL (reference range: 0–30/µL). Serial troponins
and electrocardiograms were non-suggestive of an acute coronary syndrome. Her creatinine was
1.69 mg/dL (reference range: 0.6–1.3 mg/dL). It was 1.72 two days prior above her baseline of 0.6–0.9.
Although d-dimer was 1.02 (reference range: <0.53 µg/mL), computed tomography (CT) pulmonary
embolism protocol was not done as ultrasound lower extremity vein bilateral was negative and there
was low clinical suspicion for pulmonary embolism. CT without contrast of chest/abdomen/pelvis
showed decreasing right upper lobe mass and surrounding consolidation. She had bilateral enlarging
metastatic lung nodules. Hepatic metastases were not identified but contrast was not used. Bone
metastases were unchanged. Her kidneys and urinary tract on CT and urinalysis were unremarkable.
Her acute kidney injury (AKI) was thought to be related to poor oral intake and vomiting related
volume depletion. The patient was discharged home and was recommended hydration and repeat
labs in a few days. Her creatinine on the day of discharge was 1.83 mg/dL.
Two days post discharge, the patient called her oncologist and told that she had started feeling
sick on the same day after she was discharged. She complained of fever with maximum recorded
temperature was 102.7 ◦ F along with chills and rigors. She had multiple episodes of vomiting and
poor intake. She was directly admitted to the hospital. At presentation, her vitals were stable with
a temperature of 37.0 ◦ C (98.6 ◦ F), blood pressure 140/71 mm Hg, pulse 84 beats per minute, and
respiratory rate 20 breaths per minute. Chest, cardiac, and abdominal examinations were unremarkable.
Her mucous membranes were moist. Her hemoglobin was 8.2 g/dL (reference range: 12.0–16.0 g/dL),
platelet count was 257,000/µL (reference range: 13,000–400,000/µL), white count was 2600/µL (reference
range: 4800–10,800/µL) with neutrophil count of 1500/µL (reference range: 2000–8000/µL), monocyte
count of 0/µL (reference range: 100–1300/µL), and immature granulocyte count of 50/µL (reference
range: 0–30/µL). Her low cell counts were thought to be related to her chemotherapy. No eosinophilia
was noted in complete blood count during hospitalization or prior to presentation. Her urinalysis
was negative for infection but showed 30 mg /dL (1+) proteinuria. Her blood and urine cultures
showed no growth. Her creatinine was elevated at 3.70 mg/dL and this was again thought to be
related to volume depletion. The patient was started on intravenous fluids. Her renal ultrasound
was unremarkable. With suspicion for pembrolizumab as a potential cause for acute kidney injury,
future infusions were held. The patient was given a dose of IV methylprednisone 80 mg (1 mg/kg)
and planned to be started on prednisone 80 mg daily next day. She was planned for a renal biopsy
to rule out medication-related injury. Her creatinine progressively improved during her 5-day-stay
and was 2.10 on discharge. We think this was with discontinuation of pembrolizumab. Her renal
biopsy showed evidence of acute tubular injury, focal interstitial inflammation (lymphocytes, plasma
cells, few eosinophils, few neutrophils) with focal mild tubulitis, 14% globally sclerotic glomeruli,
mild arterial thickening, and mild interstitial fibrosis (Figure 1). This was thought to be secondary to
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3. Discussion
Renal adverse effects are rare with CPIs [6]. The overall incidence of acute kidney injury was
reported to be 2.2% among 3695 patients on a CPI by Cortazar et al. [4] and 1.77% among 676
pembrolizumab by Izzedine et al. [6]. Acute kidney injury can occur at any time, from 6 to 10.5 weeks
up to 24 months after treatment initiation [4,6]. It may take 3–6 weeks for resolution [6]. No gender
predisposition has been noted [2]. Two different patterns of renal parenchymal damage have been
noted on renal biopsy, acute (granulomatous) tubulointerstitial nephritis (ATIN) and immune complex
glomerulonephritis [6]. ATIN was reported in 4 out of 12 [6], 12 out of 13 [4], and 14 out of 16 [7] with
AKI. ATIN is thought to result from loss of tolerance of self-reactive T-cells against renal antigens
by inhibition of inhibitory the PD-1/PD-L1 signaling pathway [2,4,6]. This triggers an inflammatory
response against renal parenchymal tissue manifesting as ATIN [2,6]. Shirali et al. report 6 cases of acute
interstitial nephritis in association with CPIs. Out of them, 3 were on proton pump inhibitors (PPIs)
like our patient. They theorize that initiation of PD-1 inhibitor therapy may have disrupted tolerance
to PPIs and precipitated ATIN [8]. Our patient was on pantoprazole for years for subjective acid reflux
which was continued during and after pembrolizumab was stopped. It might have contributed to the
worsened renal injury. It was continued for gastrointestinal protection as the patient was placed on
long term prednisone.
Renal biopsy is recommended in cases where AKI from pembrolizumab is suspected.
Discontinuation of pembrolizumab and initiation of corticosteroids is the mainstay of treatment [2,6,8].
Prognosis is excellent with corticosteroids [4,6]. Among the 12 patients with ATIN, 10 patients
who received glucocorticoids had partial or complete recovery of the renal function while 2 had
non-improvement in the absence of glucocorticoids [4]. Similar outcome was noted in 6 alive
pembrolizumab-treated patients who had a recovery of ~50% of their renal function [6]. Similarly,
Shirali et al. reported 6 biopsy-proven cases of interstitial nephritis with checkpoint inhibitors that
improved with discontinuation of the medication and course of corticosteroids [8]. Izzedine et al.
recommend careful corticosteroid taper over a month [6]. Mamlouk et al. used prednisone at doses
ranging between 0.5–4 mg/kg/day which was tapered off 4–24 months based on the pathology and
recurrence of renal disease [7]. Longer courses and additional immunosuppressive medications may
be needed in patients with poor response [6]. Infliximab has been tried to improve renal function [7].
Re-challenge with PD-1 inhibitor therapy can be considered with improvement in renal function and
withdrawal of any other possible offending agents [6,8]. Recurrence of severe ATIN resulted with
reintroduction of pembrolizumab. Our patient’s renal function never recovered and she progressed
to chronic kidney disease stage IV from stage II. Hence, further treatment with pembrolizumab
was aborted.
4. Conclusion
Clinicians should be aware of the potential renal complications of pembrolizumab which can lead
to a break in the treatment of the underlying condition. Early identification of an increase in creatinine
with regular monitoring may help with prevention and early institution of effective treatment.
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